Entacapone

• UNSPSC Description:

  Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 μM). Entacapone can be used for the research of Parkinson's disease[1]. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders[2].

• Target Antigen:

  COMT

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease;Neuronal Signaling

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/entacapone.html

• Solubility:

  DMSO : 33.33 mg/mL (ultrasonic)|H2O : 2 mg/mL (ultrasonic;adjust pH to 10 with NaOH)

• Smiles:

  O=C(N(CC)CC)/C(C#N)=C/C1=CC([N+]([O-])=O)=C(O)C(O)=C1

• Molecular Weight:

  305.29

• References & Citations:

  [1]E Nissinen, et al. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):262-6.|[2]Shiming Peng, et al. Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1. Sci Transl Med

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  130929-57-6